Longeveron Inc. Stock News

Longeveron is rising before the release of its Q4 2021 earnings report. Here's what investors should know about LGVN stock and why.

The shares of Longeveron (LGVN) a clinical-stage biotechnology company focused on cellular therapies have risen sharply on Wednesday ahead of its Q4 2021 results scheduled for…

Live Conference Call At 8:30 a.m. EST Live Conference Call At 8:30 a.m. EST

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B were alive and had not required a transplant betwe

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN ) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging . This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults. As a life-threatening geriatric condition, aging frailty affects up to 15% of Americans over the age of 65, or 8.1 million individuals, and manifests as a loss of muscle and decreased strength, slowed walking, low activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue. "There is increasing recognition of the unmet medical need in treating and preventing frailty in older adults, and we feel the acceptance of our trial design and rationale for publication in this prestigious, peer-reviewed journal reflects the urgency to develop potential new therapies," said Geoff Green, CEO of Longeveron.

      Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer's Disease   Trial designed to obtain safety and efficacy data of single and multiple dosing regimen   Miami, Florida—January 5, 2021 -- InvestorsHub NewsWire -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic ag...

Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

Longeveron Inc (NASDAQ: LGVN) is trading higher Wednesday after the company announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer's disease. The trial is des

The stock price of Longeveron Inc (NASDAQ: LGVN) increased by over 17% pre-market today. This is why it happened.

Longeveron Inc - Class A (LGVN) shares closed today 18.9% lower than it did at the end of yesterday. The stock is currently up 84.9% year-to-date, up 84.9% over the past 12 months, and up 84.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $19.25 and as low as $13.60 this week.Shares closed 69.6% below its 52-week high and 382.4% above its 52-week low.Trading volume this week was 36.5% lower than the 10-day average and 76.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -396.0% The company's stock price performance over the past 12 months beats the peer average by -380.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Longeveron Inc - Class A (LGVN) shares closed today 18.9% lower than it did at the end of yesterday. The stock is currently up 84.9% year-to-date, up 84.9% over the past 12 months, and up 84.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $19.25 and as low as $13.60 this week.Shares closed 69.6% below its 52-week high and 382.4% above its 52-week low.Trading volume this week was 31.9% lower than the 10-day average and 78.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -396.0% The company's stock price performance over the past 12 months beats the peer average by -380.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Longeveron Inc - Class A (LGVN) shares closed today 18.9% lower than it did at the end of yesterday. The stock is currently up 127.9% year-to-date, up 127.9% over the past 12 months, and up 127.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $19.25 and as low as $15.22 this week.Shares closed 69.6% below its 52-week high and 382.4% above its 52-week low.Trading volume this week was 17.4% lower than the 10-day average and 87.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -539.0% The company's stock price performance over the past 12 months beats the peer average by -527.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.